SDC Table 1. Clinical characteristics of patients with biopsies containing ≥15 eosinophils/hpf after second review but not pathology report
Pathology
report
count
(eosinophils/
hpf)
Second
review
count
(eosinophils/
hpf)
Initial or
follow-up
endoscopy
EoE
diagnosis
1
0
17
Follow-up
Yes
Yes, lansoprazole 15 mg/day
Elimination diet, food trialing
2
2
16
Follow-up
Yes
Yes, lansoprazole 15 mg/day
Elemental diet, food trialing
3
3
26
Follow-up
Yes
No, on ranitidine at time of initial
diagnostic endoscopy
Elimination diet, budesonide
4
3
22
Follow-up
Yes
Yes, unable to determine dose
Elimination diet, food trialing
Continued to reintroduce foods
Elimination diet
No changes to treatment
Patient
#1
PPI confirmation at diagnosis, dose
Treatment at time of listed endoscopy
Treatment change after listed endoscopy
Endoscopy considered normal, continued to
reintroduce foods
Endoscopy considered normal, continued to
reintroduce foods
Discontinued budesonide but had active EoE in
subsequent endoscopies and resumed budesonide
treatment
5
4
32
Follow-up
No
No PPI at time of diagnosis but on
PPI at time of listed endoscopy
(lansoprazole 15 mg 2X/day)
6
4
41
Follow-up
Yes
Yes, lansoprazole 30 mg/day
Fluticasone propionate
Weaned lansoprazole, decreased fluticasone
propionate dose
7
5
15
Follow-up
Yes
Yes, lansoprazole 15 mg/day
Elemental diet, food trialing
Continued to reintroduce foods
8
7
20
Follow-up
Yes
Yes, lansoprazole 15 mg/day
Elimination diet, food trialing
9
7
20
Follow-up
Yes
Yes, lansoprazole 15 mg 2X/day
Elimination diet
10
7
15
Follow-up
Yes
Yes, lansoprazole 15 mg/day
Elemental diet
11
8
16
Follow-up
Yes
No
Self-directed avoidance of foods2, oral
prednisone
Discontinued prednisone
12
8
18
Follow-up
Yes
Yes, unable to determine dose3
Elemental diet, food trialing
Current diet maintained
Elimination diet
Continued to eliminate foods
No changes to treatment, planning to reintroduce
food
No changes to treatment, considering tapering
lansoprazole
No changes to treatment, considering reintroducing
foods
13
9
16
Follow-up
Yes
No PPI at time of diagnosis but on
PPI at time of listed endoscopy
(omeprazole 20 mg/day)
14
9
21
Follow-up
Yes
Yes, lansoprazole 30 mg 2X/day
Elimination diet, fluticasone propionate
Increased fluticasone propionate dose
15
9
16
Follow-up
Yes
Yes, lansoprazole 15 mg/day
Elemental diet
Continued with elemental diet, considering
reintroducing foods
16
10
27
Follow-up
Yes
Yes, lansoprazole 15 mg 2X/day
Elimination diet, budesonide
No changes to current treatment for reflux and EoE
17
10
35
Follow-up
Yes
Yes, omeprazole 20 mg/day
Elimination diet, fluticasone propionate
Discontinued fluticasone propionate and began
elemental diet
18
10
38
Follow-up
Yes
Yes, lansoprazole 30 mg/day
Elimination diet, fluticasone propionate
No changes to treatment
19
10
16
Follow-up
Yes
Yes, lansoprazole 15 mg/day
Elimination diet, food trialing
Endoscopy considered normal, continued to
reintroduce foods
20
10
24
Follow-up
Yes
Yes, unable to determine dose3
Elimination diet, food trialing
Continued to reintroduce foods
21
12
42
Follow-up
Yes
Yes, lansoprazole 15 mg 2X/day
Elimination diet
No changes to treatment
22
14
25
Initial
No
No
None
Began lansoprazole but had no subsequent
endoscopy at CCHMC
23
14
55
Follow-up
Yes
Yes, omeprazole 10 mg/day
Fluticasone propionate
No changes to treatment
24
14
58
Follow-up
Yes
Yes, omeprazole 20 mg/day
Elimination diet, food trialing
Discontinued current food trial
1
De-identified number assigned to patient on the basis of increasing eosinophil count in pathology report
2Avoidance
3Dose
of foods based on patient preference, not physician- or skin prick test–directed
not listed in electronic medical documents
CCHMC, Cincinnati Children’s Hospital Medical Center; EoE, eosinophilic esophagitis; hpf, high-power field; PPI, proton pump inhibitor; 2X, twice